2030年北美消化不良药物市场规模与分析

北美消化不良药物市场分析与洞察

由于消化不良患病率的不断上升以及不健康生活方式的日益盛行，北美消化不良药物市场预计在预测期内将实现增长。代谢紊乱患病率的不断上升也对市场产生了影响。然而，治疗消化不良的药物可能产生的副作用以及人们对天然和草药疗法的日益偏爱预计将阻碍北美消化不良药物市场的发展。人口老龄化加剧和药物审批的增加预计将为市场增长带来机遇。然而，严格的法规和民众对消化不良缺乏认识预计将对市场增长构成挑战。

Data Bridge Market Research分析，北美消化不良药物市场预计在2023年至2030年的预测期内以5.6%的复合年增长率增长。

报告指标	细节
预测期	2023 至 2030 年
基准年	2022
历史岁月	2021（可定制为 2015 - 2020）
定量单位	收入（千）、销量（个）、定价（美元）
涵盖的领域	类型（器质性消化不良、非溃疡性消化不良、药物性消化不良等）、治疗类型（药物和手术）、药物类型（品牌药和仿制药）、处方药（非处方药和处方药）、给药途径（口服和注射）、性别（男性和女性）、最终用户（医院、诊所、家庭护理机构、专科诊所、门诊手术中心、学术和政府研究机构等）、分销渠道（直接招标和零售销售）
覆盖国家	美国、加拿大和墨西哥
涵盖的市场参与者	其中包括拜耳公司、卡迪拉制药、赛诺菲、鲁宾、雅培、百利戈公司、阿斯利康、宝洁、利洁时等。

市场定义

消化不良，通常称为消化不良，是指进食后腹部疼痛和不适。它通常是潜在疾病的征兆，例如 GERD（胃食管反流病）、胆囊和溃疡病。消化不良的治疗取决于病因和严重程度。治疗潜在疾病或更换药物可以减轻消化不良。消化不良分为两大类：“器质性”和“功能性消化不良”（FD）。消化不良的器质性病因包括消化性溃疡、胃食管反流病、胃癌或食管癌、胰腺或胆道疾病、食物或药物不耐受以及其他感染性或全身性疾病。功能性消化不良（dis-PEP-see-uh）是指没有明显原因的反复胃部不适症状。功能性消化不良也称为非溃疡性消化不良。

北美消化不良药物市场动态

本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：

司机

消化不良患病率不断上升

消化不良，俗称消化不良，是一种影响北美数百万人的胃肠道疾病。这种疾病会导致不适、疼痛和上腹部饱胀感。消化不良可能是由多种因素引起的，例如进食过快、食用辛辣或油腻食物，或药物的副作用。

消化不良患病率的上升是消化不良药物市场增长的关键驱动因素之一。消化不良发病率的上升可归因于生活方式、饮食习惯的改变和人口老龄化等多种因素。随着年龄的增长，人们更容易出现消化问题，包括消化不良。随着老年人口的增加，对消化不良药物的需求也随之增加。

此外，由于消化不良的发病率不断上升，各种消化系统疾病（如肠易激综合征、胃轻瘫、胃炎和消化性溃疡）也会导致消化不良。因此，消化不良和其他导致消化不良的消化系统疾病的发病率不断上升，预计将成为市场增长的驱动力。使用消化不良药物缓解消化不良症状和治疗消化不良有可能改善患者的治疗效果并减轻消化不良的负担。因此，消化不良发病率的不断上升推动了全球对消化不良药物的需求，从而增加了消化不良在人群中的发病率和患病率。

不健康生活方式的普及

近年来，不健康的生活方式越来越多，导致消化不良的患病率上升。不健康的生活方式，如食用大量加工食品、缺乏运动和过量饮酒都可能导致消化不良。

因此，随着人们寻求缓解消化不良症状，对消化不良药物的需求也相应增加。消化不良药物市场已经通过各种药物来满足这种需求，包括质子泵抑制剂、H2 受体拮抗剂和抗酸药。

不健康生活方式的增加可以归因于多种因素，包括饮食习惯的改变、压力水平的增加以及久坐不动的生活方式。现代生活通常以工作时间长、压力大以及快餐和其他不健康食品的易得性为特征。这些因素可能导致消化不良和其他相关疾病，如胃食管反流病 (GERD)。

总之，消化不良是一种常见疾病，可由多种因素引起，包括不健康的生活方式。不健康生活方式的增加导致消化不良患病率上升，对有效消化不良药物的需求也相应增加，这有望成为市场增长的动力。

机会

老龄人口不断增长

据估计，到 2050 年，65 岁及以上人口的数量预计将达到 15 亿，这表明世界人口正在迅速老龄化和老化。随着年龄的增长，人们患慢性疾病的风险更高。这包括消化不良等消化系统疾病，这些疾病可能是衰老的结果。

人口增长和老龄化为消化不良药物市场带来了巨大的扩张机会。由于越来越多的人出现消化系统问题，因此对有效治疗的需求也越来越大，这些治疗可以减轻症状的严重程度并提高他们整体的生活质量。

此外，消化不良的治疗可能需要专门针对老龄人口的需求。老年人可能患有多种慢性病，同时服用多种药物，这两者都会增加药物相互作用和副作用的可能性。因此，老年人需要既安全又有效的消化不良药物。随着年龄的增长，人们的体力和免疫力也会下降，导致包括消化不良在内的多种胃病发病率不断上升。

因此，人口老龄化导致的消化不良及其症状的增加以及人们对预防性医疗保健的偏好预计将为消化不良药物市场的增长提供机会。

克制/挑战

民众对消化不良缺乏认识

技能短缺已经影响到了整个国家，越来越多的人被迫等待六个月以上的牙科治疗。由于技术进步、基础设施和其他一些因素，新兴国家或发展中国家消化不良药物领域的熟练专业人员短缺。

缺乏熟练的专业人员的部分原因是成为牙科专业人员需要接受严格的教育和培训，以及竞争激烈的就业市场。此外，熟练的牙医需要更多经过正式培训、获得执照的牙科助理来帮助维持和增加获得口腔保健的机会，以操作和执行消化不良药物系统等先进的技术系统。

新兴国家缺乏熟练的专业人员，他们无法有效运用新技术。这可能会给新技术的市场发展带来挑战，因为这些国家正在推迟技术驱动的市场进步。

最新动态

2023年4月，赛诺菲宣布完成对Provention Bio, Inc.的收购，此次收购有助于公司拓展普药业务。
2022 年 7 月，ANI Pharmaceuticals, Inc. 宣布从私营生物制药公司 Oakrum Pharma, LLC 购买四个简化新药申请 (ANDA)。

北美消化不良药物市场细分

北美消化不良药物市场细分为类型、治疗类型、药物类型、处方、给药途径、性别、最终用户和分销渠道。细分市场之间的增长有助于您分析利基增长领域和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

类型

非溃疡性消化不良
器质性消化不良
药物引起的消化不良
其他的

根据类型，北美消化不良药物市场分为器质性消化不良、非溃疡性消化不良、药物性消化不良等。

治疗类型

药物
外科手术

根据治疗类型，北美消化不良药物市场分为药物治疗和手术治疗。

药物类型

品牌
通用的

根据药物类型，北美消化不良药物市场分为仿制药和品牌药。

处方

无需处方药
处方药

根据处方，北美消化不良药物市场分为非处方药和处方药。

给药途径

口服
注射剂

根据给药途径，北美消化不良药物市场分为口服和注射。

性别

男性
女性

根据性别，北美消化不良药物市场分为男性和女性。

最终用户

医院
诊所
家庭护理设置
专科诊所
流动中心
学术和政府研究机构
其他的

根据最终用户，北美消化不良药物市场分为医院、诊所、家庭护理机构、专科诊所、门诊手术中心、学术和政府研究机构等。

分销渠道

直接招标
零售销售

根据分销渠道，北美消化不良药物市场分为直接招标和零售。

北美消化不良药物市场区域分析/见解

对北美消化不良药物市场进行分析，并根据类型、治疗类型、药物类型、处方、给药途径、性别、最终用户和分销渠道提供市场规模洞察和趋势。

本市场报告涵盖的国家包括美国、加拿大和墨西哥。

由于美国医疗支出的增加和代谢紊乱的高发病率，预计美国将主导北美消化不良药物市场。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在对国家数据进行预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战以及国内关税和贸易路线的影响。

竞争格局和北美消化不良药物市场份额分析

北美消化不良药物市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

该市场的一些主要市场参与者包括拜耳公司、卡迪拉制药公司、赛诺菲、鲁宾公司、雅培、百利戈公司、阿斯利康、宝洁和利洁时等。

SKU-70077

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 2 NORTH AMERICA NON-ULCER DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 3 NORTH AMERICA ORGANIC DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 NORTH AMERICA DRUG INDUCED DYSPEPSIA IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 5 NORTH AMERICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 8 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 9 NORTH AMERICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 NORTH AMERICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 11 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 13 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 15 NORTH AMERICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 16 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 17 NORTH AMERICA SURGERY IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 19 NORTH AMERICA GENERIC IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 NORTH AMERICA BRANDED IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 22 NORTH AMERICA WITHOUT PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 23 NORTH AMERICA PRESCRIPTION DRUGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 25 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 26 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 27 NORTH AMERICA INJECTABLE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 28 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 29 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 31 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 32 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 33 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 34 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 35 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 36 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 37 NORTH AMERICA CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 38 NORTH AMERICA HOMECARE SETTINGS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 39 NORTH AMERICA SPECIALTY CLINICS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 40 NORTH AMERICA AMBULATORY CENTERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 41 NORTH AMERICA ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 42 NORTH AMERICA OTHERS IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 43 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 44 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 45 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 46 NORTH AMERICA DIRECT TENDER IN DYSPEPSIA DRUG MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 47 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 48 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 49 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 NORTH AMERICA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 51 NORTH AMERICA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 52 NORTH AMERICA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 NORTH AMERICA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 55 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 56 NORTH AMERICA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 57 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 NORTH AMERICA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 59 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 NORTH AMERICA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 61 NORTH AMERICA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 62 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 63 NORTH AMERICA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 64 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 65 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 66 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 67 NORTH AMERICA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 68 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 69 NORTH AMERICA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 70 NORTH AMERICA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 71 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 72 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 73 NORTH AMERICA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 74 NORTH AMERICA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 75 NORTH AMERICA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 76 U.S. DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 U.S. DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 78 U.S. MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 79 U.S. DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 80 U.S. ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 81 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 83 U.S. PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 84 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 86 U.S. H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 87 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 88 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 89 U.S. GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 90 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 91 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 92 U.S. ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 93 U.S. NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 94 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 95 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 96 U.S. PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 97 U.S. DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 U.S. BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 99 U.S. DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 100 U.S. DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 101 U.S. ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 102 U.S. DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 103 U.S. FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 104 U.S. MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 105 U.S. DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 106 U.S. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 107 U.S. HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 108 U.S. DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 109 U.S. RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 110 CANADA DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 111 CANADA DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 112 CANADA MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 113 CANADA DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 CANADA ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 115 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 116 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 117 CANADA PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 118 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 120 CANADA H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 121 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 122 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 123 CANADA GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 124 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 126 CANADA ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 127 CANADA NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 128 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 129 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 130 CANADA PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 131 CANADA DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 132 CANADA BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 CANADA DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 134 CANADA DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 135 CANADA ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 136 CANADA DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 137 CANADA FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 138 CANADA MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 139 CANADA DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 140 CANADA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 CANADA HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 142 CANADA DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 143 CANADA RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 144 MEXICO DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 145 MEXICO DYSPEPSIA DRUG MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 MEXICO MEDICATION IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 147 MEXICO DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 148 MEXICO ANTACID IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 149 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 151 MEXICO PROTON PUMP INHIBITORS (PPI'S) IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 152 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 153 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 154 MEXICO H2 BLOCKERS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 155 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 156 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 157 MEXICO GASTRIC PROKINETIC GENDERNTS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 158 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 159 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 160 MEXICO ANTIBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 161 MEXICO NON DRUGS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 162 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 163 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (THOUSAND UNITS)

TABLE 164 MEXICO PROBIOTICS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (ASP)

TABLE 165 MEXICO DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 166 MEXICO BRANDED IN DYSPEPSIA DRUG MARKET, BY DRUG TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 MEXICO DYSPEPSIA DRUG MARKET, BY PRESCRIPTION, 2021-2030 (USD THOUSAND)

TABLE 168 MEXICO DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 169 MEXICO ORAL IN DYSPEPSIA DRUG MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 170 MEXICO DYSPEPSIA DRUG MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 171 MEXICO FEMALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 172 MEXICO MALE IN DYSPEPSIA DRUG MARKET, BY AGE, 2021-2030 (USD THOUSAND)

TABLE 173 MEXICO DYSPEPSIA DRUG MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 174 MEXICO HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 175 MEXICO HOSPITALS IN DYSPEPSIA DRUG MARKET, BY TIER, 2021-2030 (USD THOUSAND)

TABLE 176 MEXICO DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 177 MEXICO RETAIL SALES IN DYSPEPSIA DRUG MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

图片列表

FIGURE 1 NORTH AMERICA DYSPEPSIA DRUG MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA DYSPEPSIA DRUG MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA DYSPEPSIA DRUG MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA DYSPEPSIA DRUG MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA DYSPEPSIA DRUG MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA DYSPEPSIA DRUG MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA DYSPEPSIA DRUG MARKET: MULTIVARIATE MODELLING

FIGURE 8 NORTH AMERICA DYSPEPSIA DRUG MARKET: DBMR MARKET POSITION GRID

FIGURE 9 NORTH AMERICA DYSPEPSIA DRUG MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 NORTH AMERICA DYSPEPSIA DRUG MARKET: MARKET END-USER COVERAGE GRID

FIGURE 11 NORTH AMERICA DYSPEPSIA DRUG MARKET: SEGMENTATION

FIGURE 12 INCREASE IN THE PREVALENCE OF METABOLIC DISORDERS IS EXPECTED TO DRIVE THE NORTH AMERICA DYSPEPSIA DRUG MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030

FIGURE 13 NON-ULCER DYSPEPSIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET IN 2023 & 2030

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA DYSPEPSIA DRUG MARKET

FIGURE 15 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, 2022

FIGURE 16 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 17 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 18 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE, LIFELINE CURVE

FIGURE 19 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , 2022

FIGURE 20 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)

FIGURE 21 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , CAGR (2023-2030)

FIGURE 22 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TREATMENT TYPE , LIFELINE CURVE

FIGURE 23 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2022

FIGURE 24 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, 2023-2030 (USD THOUSAND)

FIGURE 25 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 26 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 27 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2022

FIGURE 28 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, 2023-2030 (USD THOUSAND)

FIGURE 29 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, CAGR (2023-2030)

FIGURE 30 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY PRESCRIPTION, LIFELINE CURVE

FIGURE 31 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 32 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD THOUSAND)

FIGURE 33 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 34 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 35 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, 2022

FIGURE 36 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, 2023-2030 (USD THOUSAND)

FIGURE 37 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 38 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY GENDER, LIFELINE CURVE

FIGURE 39 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, 2022

FIGURE 40 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 41 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, CAGR (2023-2030)

FIGURE 42 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 44 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 45 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 46 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 47 NORTH AMERICA DYSPEPSIA DRUG MARKET: SNAPSHOT (2022)

FIGURE 48 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022)

FIGURE 49 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2023 & 2030)

FIGURE 50 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY COUNTRY (2022 & 2030)

FIGURE 51 NORTH AMERICA DYSPEPSIA DRUG MARKET: BY TYPE (2023-2030)

FIGURE 52 NORTH AMERICA DYSPEPSIA DRUG MARKET: COMPANY SHARE 2022 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

At what growth rate will the market be projected to grow during the forecast period of 2023 to 2030?

The North America Dyspepsia Drug Market is projected to grow at a CAGR of 5.6% during the forecast period by 2030.

Which market segments are covered in this report?

The North America Dyspepsia Drug Market is segmented on the basis of type, treatment type, drug type, prescription, route of administration, gender, end user, and distribution channel.

Who are the major players operating in the market?

The major players in the North America Dyspepsia Drug Market are Bayer AG, Cadila Pharmaceuticals., Sanofi, Lupin., Abbott., Perrigo Company plc, AstraZeneca, Procter & Gamble, and Reckitt Benckiser among others.

Which countries data are covered in the report?

The countries covered in the North America Dyspepsia Drug Market are U.S., Canada, and Mexico.

Forecast Period	2024 –2030
Market Size (Base Year)	USD MILLION Request
Market Size (Forecast Year)	USD MILLION Request For Unlock
CAGR	5.60 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

北美消化不良药物市场 – 行业趋势和 2030 年预测

北美消化不良药物市场 – 行业趋势和 2030 年预测

North America Dyspepsia Drug Market

CAGR : 5.60 %

北美消化不良药物市场分析与洞察

北美消化不良药物市场动态

北美消化不良药物市场细分

北美消化不良药物市场区域分析/见解

竞争格局和北美消化不良药物市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

北美消化不良药物市场 – 行业趋势和 2030 年预测

北美消化不良药物市场 – 行业趋势和 2030 年预测

North America Dyspepsia Drug Market

CAGR : 5.60 %

北美消化不良药物市场分析与洞察

北美消化不良药物市场动态

北美消化不良药物市场细分

北美消化不良药物市场区域分析/见解

竞争格局和北美消化不良药物市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面